Compare GECC & PMVP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GECC | PMVP |
|---|---|---|
| Founded | 2016 | 2013 |
| Country | United States | United States |
| Employees | N/A | 54 |
| Industry | Finance: Consumer Services | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 84.6M | 71.1M |
| IPO Year | 2016 | 2020 |
| Metric | GECC | PMVP |
|---|---|---|
| Price | $5.23 | $1.37 |
| Analyst Decision | Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $10.75 | N/A |
| AVG Volume (30 Days) | 61.0K | ★ 763.6K |
| Earning Date | 05-12-2026 | 05-08-2026 |
| Dividend Yield | ★ 22.06% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.41 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $0.92 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $12.88 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.63 | $1.02 |
| 52 Week High | $10.88 | $1.88 |
| Indicator | GECC | PMVP |
|---|---|---|
| Relative Strength Index (RSI) | 34.61 | 47.51 |
| Support Level | $5.08 | $1.06 |
| Resistance Level | $5.37 | $1.50 |
| Average True Range (ATR) | 0.21 | 0.09 |
| MACD | -0.07 | -0.02 |
| Stochastic Oscillator | 0.00 | 18.37 |
Great Elm Capital Corp is an externally managed, non-diversified closed-end management investment company. It generates both income and capital appreciation through debt and income-generating equity investments, including investments in finance businesses. The Company operates as a single reportable segment with an investment objective to generate both current income and capital appreciation through debt and equity investments and manages the business on a consolidated basis.
PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which can eliminate cancer cells. The key product candidate, rezatapopt, is designed to be an orally available small molecule that structurally corrects the mutant p53 protein with the Y220C mutation. Currently, the product candidates are undergoing preclinical and clinical testing, and company relies on third parties for the manufacture after marketing approvals.